Key facts
- It has raised $14.9M; the latest was Accelerator/Incubator in Oct 2025.
- Notable investors include Bpifrance, AWS Startups, Speedinvest, Agoranov, Verve Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Orakl Oncology
- ·The full record, as it builds
Funding rounds
No funding rounds for Orakl Oncology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Orakl Oncology
Developer of an artificial intelligence and biology-native platform designed to support cancer drug discovery and development. The company offers real-patient data integration and predictive modeling to forecast clinical trial responses, enabling pharmaceutical researchers to de-risk studies, identify drug targets, and accelerate regulatory progress.
- Sector
- Healthcare
- HQ
- Villejuif, France
- Founded
- 2023
- Employees
- 25
- Website
- orakl-oncology.com/
- Ownership
- Privately Held (backing)
Orakl Oncology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Orakl Oncology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Orakl Oncology in its N-PORT filings yet. We sweep new filings monthly.